Erratum: The Quest for Secondary Pharmaceuticals: Drug Repurposing/Chiral-Switches Combination Strategy (ACS Pharmacology and Translational Science (2023) 6: 2 (201-219) DOI: 10.1021/acsptsci.2c00151)

Page 209, bottom of left column. Dr. Sheila DeWitt (DeuteRx, LLC, Bedford, NH, USA; email: [email protected]) has recently drawn our attention to a mistake in the following sentence: “The deuterated S-enantiomer of lenalidomide DP-053 (formerly CTP-221, Figure 2) was shown to be ‘greatly stabilized to epimerization and results in a more desirable pharmacokinetic profile than racemic lenalidomide’ 115 (see also ref 108, ref 56 therein).” There was also a mistake in ref 115 that was cited in that text, which is corrected in ref 1 herein. DP-053 was not formerly CTP-221. They are two different compounds that were pursued separately by Deuteria Pharmaceuticals, Inc. and Concert Pharmaceuticals, Inc., respectively. DP-053 is the structure shown in Figure 2 (D1-S-lenalidomide) which was pursued by Deuteria Pharmaceuticals, Inc. Celgene Corporation (now Bristol-Myers Squibb Company) acquired Deuteria and selected assets, including DP-053, in December 2012. The remaining assets were spunout into DeuteRx, LLC. CTP-221 is D5-S-lenalidomide, which was pursued by Concert Pharmaceuticals, Inc. and then part of a development and license agreement with Celgene Corporation (now Bristol-Myers Squibb Company) in May 2013. The text should have stated that “CTP-221 was shown to be ‘greatly stabilized to epimerization and results in a more desirable pharmacokinetic profile than racemic lenalidomide’ 115 (see also ref 108, ref 56 therein).” (Figure Presented). We apologize for the above-mentioned mistakes. Other data shown in the published Perspective are correct, and this modification does not affect the overall conclusions of our study.